Clinical Trial Search

Primary: Pathologic Complete Response Rate (PCRR), the Percentage of Patients Who Have No Evidence of Cancer in the Breast or Lymph Nodes Following Surgery — 56 percentage of…

Primary: Progression-Free Survival (PFS) — 7.4; 3.8; 4.4 months — p=0.003

Primary: Change in Average (Follow-up - Baseline) From All Biopsies — -0.23; -0.02 WHO Units

Primary: Biopsy Proven Acute Rejection (BPAR) — 2.3; 9.1; 10.7; 5.8 percentage of participants

Primary: Measure Patient Response to High-dose Cytarabine Followed by Clofarabine in Adult Patients With Relapsed or Refractory AML — 17 participants

Primary: Statistically Significant (p<0.05) Decrease From Baseline in Yale Brown Obsessive Compulsive Scale Modified for Pathological Gambling — 13.9 YBOCS score

Primary: Severity of Pruritis — 10.88; 9.76; 6.64; 5.12 units on a scale

Primary: Individual Patient Overall Success — 142; 98 participants

Primary: Complete Response + Partial Response + Stable Disease > 24 Weeks — 35 participants

Primary: Methacholine Challenge Test Result for Phase 2 — 1.19; 2.04 mg/ml — p=0.65

Primary: Percentage of Participants With Intraoperative Hemostasis at 4 Minutes After Treatment Application — 82.9; 37.1 percentage of participants — p=<0.001

Primary: Percentage of Participants Achieving an American College of Rheumatology Criteria (ACR20) Response at Week 24 — 69.4; 73.4 Percentage of participants

Primary: Cumulative Probability of Testosterone at Castrate Level (≤0.5 ng/mL) From Day 28 to Day 196 — 96.7 percent probability

Primary: Change in Pain Score From Day 1 to Day 10 — -3.3 units on a scale

Primary: High Density Lipoprotein Cholesterol (HDL-c) — 36.5; 36.8; 41.6; 35.8 mg/dL — p=<0.0001